Clinical trials. A new antimonilial drug. A report from the general practitioner research group.
D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001593:Benzyl Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002176:Candida albicans / Q000187:drug effects*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D002648:Child; D004987:Ethers / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007973:Leukorrhea / Q000188:drug therapy; D008598:Menstruation; D008875:Middle Aged; D011539:Pruritus Vulvae / Q000188:drug therapy; D012007:Rectum / Q000382:microbiology; D014621:Vagina / Q000382:microbiology
D000935:Antifungal Agents; D001593:Benzyl Compounds; D004987:Ethers; D007093:Imidazoles